NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

Any radiation oncologist will be familiar with GBM. Radiation is part of the standard of care, poor as it is. I’m sure Dr. Hahn has treated patients with GBM.

He may not be familiar with our P3 trial, but there are only about 4-5 significant ongoing P3 trials in GBM. When the data is presented, it should speak for itself and be quite compelling. He should be able to decipher what a long immunotherapy survival tail would mean to GBM patients. All the oncologists I speak with understand it. Dr. Hahn is an oncologist.

I’m not sure how his view from the top will effect our trial, but he will be familiar with the disease and the frustrating lack of progress on treating the disease in the past 50 years. That can’t hurt, if our results are as positive as interim data suggests.